← Leaderboards
Courtney D Fitzhugh
Vanderbilt University Medical Center
$1,016,311
Attributed
$4,065,243
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $854.9K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,065,243 · 1
By mechanism
U01$4,065,243 · 1
Top collaborators
- Michael Rutledge Debaun5 shared
- Debra L Friedman5 shared
- Lydia Pecker3 shared
- Richard J Jones2 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Alexander Bick$5,781,681
- Debra L Friedman$19,684,821
- Michael Rutledge Debaun$40,846,229
- Natasha Bassam Halasa$37,609,939
- David G Harrison$36,205,139
Others in their field
Other Emerging Leaders on “Academic Medical Centers”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Lisa Newman · Research Triangle Institute$22,725,934
- Craig Reist · Research Triangle Institute$22,725,934
- Scott Topper · Broad Institute, Inc.$20,157,828
- Molly Wasko · University Of Alabama At Birmingham$18,626,873
Research focus
Academic Medical CentersFundingAdult Stem Cell TransplantationAdverse OutcomeAllogenicAdultChildChimerismClinical CenterClinically SignificantClinical RiskClonal EvolutionCessation Of LifeCohortCohort StudiesCurative TreatmentsDesignEnrollmentFamilyFertilityFinancial ToxicityFollow-UpFunctional DisorderGenes
Grant awards (5)
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$841,945
U01 · FY2025 · HL
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$827,619
U01 · FY2024 · HL
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$849,699
U01 · FY2023 · HL
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$854,865
U01 · FY2022 · HL
Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease$691,115
U01 · FY2021 · HL